Pacira BioSciences reports record-high EXPAREL sales in the fourth quarter of 2025, driven by volume growth of 7 percent.
The company also highlights growth in other product sales, showcasing a positive performance across its portfolio.
Preliminary unaudited revenue for the full year 2025 stands at $726.4 million, marking a year-over-year increase.
EXPAREL Sales Surge
EXPAREL net product sales reached $155.8 million in the fourth quarter, showing a 7 percent growth from the previous year.
Strategic Progress
CEO Frank D. Lee emphasizes solid execution and progress on 5x30 strategic priorities leading to sustainable success.
Share Repurchase Program
Pacira repurchased 2.0 million shares of common stock in the fourth quarter for $50.0 million, indicating confidence in the company's future.
Employee Inducement Awards
Pacira granted inducement awards to new employees under the Inducement Plan, demonstrating a commitment to talent acquisition and retention.
- Strong EXPAREL volume growth in the second half of 2025 reflects value from commercial investments.
- Company's revenue diversity from various product lines contributes to overall financial stability.
Pacira BioSciences closes 2025 with robust revenue performance, driven by EXPAREL sales and strategic advancements. The company's focus on non-opioid pain therapies positions it for continued growth in 2026.